Aim: Evaluate the impact of MAGIC trial on gastric adenocarcinoma's management in Africa. Method and methodology: It was about a review of literature on therapeutic aspects of gastric adenocarcinoma in the African area. We have taken a census of 21 articles including 2792 patients published between 1980 and 2013. We have distinguished articles published before 2006 (group 1) from those published after 2006 (group 2) to better understand therapeutic changes after that perioperative chemotherapy has become a standard in gastric adenocarcinoma's management. Results: Surgery remains in Africa the first and practically the only treatment weapon in gastric adenocarcinoma: 46% to 92% people in the 1st group and 65% to 100% people in the 2nd group underwent surgical procedures. Perioperative chemotherapy takes longer to be part of therapeutic habits (0.18%). Factors related to patients such alteration of general state with a WHO performance status superior to 2 in 72% of cases, the lack of financial accessibility to anticancerous drugs explains partly the non-use of perioperative chemotherapy. This is also due to factors peculiar to our sanitation structures which don't have enough cancer specialists. So we noticed that MAGIC trial is simply ignored in certain studies. The lack of adoption of perioperative chemotherapy explains with delayed diagnosis the low survival of patients in the African area. Conclusion: MAGIC trial practically has no effect on therapeutic behavior yet comparatively to gastric adenocarcinoma in Africa. The insurance particularly relies on surgery only until now. However, it might enable us to improve gastric adenocarcinoma's survival rates.
Introduction
Gastric adenocarcinoma is a malignant proliferation developed at the expense of the gastric mucosa glandular epithelium [1] . For long, surgery has been the only means of therapy. This was reinforced in 1980 by a French study that noted that survival was not improved by adjuvant chemotherapy [2] . Disease-free survival at 5 years has improved with the American MAC DONALD trial in 2000, which advocated concurrent adjuvant radiochemotherapy [3] . Ultimately, it is the MAGIC trial that stood out in 2006, and standardised perioperative chemotherapy in cases of avanced stage stomach adenocarcinomas, that is to say, corresponding to non-metastatic IB [1] [4] [5] . Overall 5 years survival rate was improved (23% vs. 36.30%) [3] . This chemotherapy has been adopted in almost all Western countries [1] [5] [6] [7] [8] .
In African countries where this type of cancer is common, MAGIC trial appears not to be applied due to African context-specific factors. This literature review aims to make a synthesis of stomach adenocarcinoma therapeutic modalities in Africa, so as to improve its treatment.
Patients and Methods
This literature review focuses on therapeutic aspects of stomach adenocarcinoma in African context. Are taken into account all publications:
• Indexed or not by Medline;
• Released in national and international journals;
• In the annals of various Africa universities;
• Contained in the African congress synopsis booklets (Francophone Africa Surgeons' Association congress Euro-African Oncologists' congress, West African College of Surgeons' conference(WACS), and national congresses as well. For data collection, African colleagues were directly contacted for some publications.
A total number of 26 articles dealing with therapeutic aspects of gastric adenocarcinoma were collected. Five (5) articles, including 3 dealing exclusively with epidemiological aspects and 2 with questionable methodology and results, were discarded.
Finally, 21 African articles on gastric adenocarcinoma therapy, including 18 retrospective and 3 prospective, constituted the bulk of this literature review [9] - [29] . These 21 articles involved 2792 patients. The articles are subdivided into two distinct groups-those published before 2006 (Group 1) and the others released after 2006 (group 2)-to better understand therapeutic changes after perioperative chemotherapy has been standardised in the treatment of gastric adenocarcinomas. Group 1 consisted of nine articles involving 933 patients. Group 2 is made of twelve articles with 1859 patients. The assessment stressed factors influencing therapeutic indications such as diagnosis time, diagnosis stages, and patients' general condition at diagnosis, therapeutic indications, the different medical and surgical treatments, and finally prognostic aspects. This allowed assessing the impact of the MAGIC trial in the treatment of gastric adenocarcinoma in African context.
Results

Therapeutic and Prognostic Aspects of Gastric Adenocarcinoma in Africa before 2006, MAGIC Trial Publication Date
The mean diagnosis average time was 9.35 months. Stages III and IV represented over 80% of gastric adenocarcinoma cases. Surgery has been the mainstay of treatment. None of the studies mentioned chemotherapy and radiotherapy.
Operability rates ranged from 46% to 92%. Total gastrectomy was performed in 5.56% to 55% of cases and partial gastrectomy in 18.97% to 95% cases. Gastroenteroanastomosis was performed in 11% to 54% cases. D1 type lymphadenectomy was noted in two studies. Lost patient rates ranged from 21.43% to 92.45%. One-year survival was mentioned in 4 studies, and constitutes 7% to 31% of cases. Five-year survival was mentioned in one study (2.38%).
Therapeutic and Prognostic Aspects of Gastric Adenocarcinomas in Africa after the Perioperative Chemotherapy Became a Standard (after 2006)
The average of mean diagnosis times was 12.92 months with extremes of 0. Table 1 .
Operability rates ranged from 65.5% to 100%. Gastrectomy was total in 0.43% to 40% of cases and partial in 60% to 100% of cases. Gastroenteroanastomosis was performed in 39% to 65% cases and alimentary gastrostomy in 0% to 16.5% of cases. Lymphadenectomy was mentioned in six out of twelve studies. The D1, D1.5 and D2 types respectively accounted for 58.20%, 22.39% and 19.41% of cases.
Radiotherapy was used in gastric adenocarcinoma treatment in two studies.
Fifteen patients benefited from it, including 3/21 in South Africa (2011) and 12/232 in Tanzania (2012). Doses, numbers of sessions and toxicity were not specified.
Overall survival rate was specified in ten out 12 studies. It was 32% at 6 months (1/10: Mali). At one year survival rate ranged from 15.50% to 70.10%. 5
years survival rate ranged from 6.90% to 21.80%. Lost patients' rates were specified in three studies, and ranged from 11.11% to 67.24%. Perioperative mortality rate was 2.810% to 22.10% of operated cases.
Synthetic Studies
The overall average diagnosis time was 11 months. The diagnosis time in groups Patients' WHO performance status was not specified in Group 1. It was higher than 2 in 72% of cases in group 2.
• Chemotherapy Table 2 .
• Surgery Operability rates ranged from 46% to 92% in group 1 and 65% to 100% in group 2.
Partial gastrectomy was prevalent in both groups with 80.11% in group 1 and 80.9% in group 2 (p > 0.05).
Surgery remained the main gastric adenocarcinoma treatment. However, lymphadenectomy modalities were more stressed by the studies in group 2 than in group 1. The D1 treatment was the most practised. 
Prognosis
Mortality rate after 1 month reached 33.33% in group 1 and 22.10% in group 2 (p > 0.05). The 1-year survival rate was 31% in group 1 and 70% in group 2 (p < 0.001). And 5-year survival rate was 2.38% in group 1 and ranged from 6.9% to 21.8% in group 2.
The rate of lost patients amounted to 92.45% in group 1 against 67.24% in group 2 (p < 0.001).
Discussion
The Key Elements for Therapeutic Indications
• Diagnosis time
The overall diagnosis mean time was 11 months. There was no significant gap between group 1 and group 2 (9.35 months vs. 12.92 months (p > 0.05). These periods are nevertheless longer than in Western, Asian and Middle-East countries [30] [31] [32] where they vary from 3 to 4 months. Generally, gastric adenocarcinoma diagnosis time is longer in Africa. This could be explained by a delayed resorting to medical facilities due to the fact that traditional therapy still remains the first alternative. Poverty, lower social status and lack of health coverage do significantly limit access to specialised health facilities.
Diagnosis Stage
Stages II, III and IV accounted for 97.18% and 96.84% of cases respectively in groups 1 and 2 (p > 0.05). These diagnosis stages are similar to some European and Asian data despite the gap in diagnosis time [30] [33] [34] . The higher rates of advanced stages at diagnosis are accounted for by delayed diagnoses, and the lack of early specific signs [33] . Instituting a systematic stomach cancer screening and an effective monitoring policy for populations at-risk in countries such as Japan [35] contributed to reduce the rate of advanced stages. Diagnosis stages dictate therapeutic indications and determine prognosis.
General Condition of Patient
The majority of patients in group 2 had a performance status, which was according to WHO, higher than or equal to 2 (over 72%). [38].
In Africa, in some cases, patients could benefit from chemotherapy after sound resuscitation (parenteral nutrition, blood transfusion, fluid and electrolyte rebalancing). This would improve the results of gastric cancer treatment. Unfortunately, such resuscitation facilities, especially for parenteral nutrition, remain inaccessible.
Comparing the Impact of the MAGIC Trial on Gastric Adenocarcinoma Surgical Practices in Africa and in the West
Perioperative chemotherapy should be the norm once an IB stage is reached [1] [5] [7] . In other words, dependent on diagnosis stages revealed by our meta- Table 3 comparatively summarises the rate of framed surgery between our study and non-African studies.
Prognosis Aspects
The overall 5-year survival rate in our study ranged from 0 and 21.8%. However, it remains lower than that of GLEHEN et al. [30] France, CUNNINGHAM et al. [4] England and WU et al. [36] in China, SASAKO et al. [40] in Japan. The higher survival rates in the European and Asian literatures are explained by the availability of chemotherapy in addition to surgery, the existence of equipped cancer centers with qualified practitioners and especially social security in those countries.
Conclusion
This literature review shows gastric adenocarcinoma is lately diagnosed, which accounts for advanced stages and patients' poor general condition. Though perioperative chemotherapy has become a standard in Western countries since the adoption of the MAGIC trial in 2006, it is still not a common practice in the African context. Poor general condition of patients, lack of drugs, financial inaccessibility, and the lack of cancer specialists could account for the non-use of perioperative chemotherapy. Surgery remains therefore the only therapeutic means for adenocarcinoma treatment in our areas. Nevertheless, adopting the MAGIC trial would substantially improve gastric adenocarcinoma prognosis.
